Shares of GlaxoSmithKline PLC (NYSE:GSK) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $45.50 and last traded at $45.43, with a volume of 1,208,518 shares changing hands. The stock had previously closed at $45.25.

Several analysts recently issued reports on the stock. Beaufort Securities restated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Tuesday. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, July 27th. Goldman Sachs Group Inc. restated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Thursday, July 28th. BNP Paribas restated a “neutral” rating on shares of GlaxoSmithKline PLC in a research report on Sunday. Finally, Citigroup Inc. restated a “buy” rating on shares of GlaxoSmithKline PLC in a research report on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $46.86.

The stock’s 50 day moving average price is $42.90 and its 200-day moving average price is $41.56. The firm has a market cap of $110.66 billion and a P/E ratio of 2845.62.

The firm also recently declared a dividend, which will be paid on Thursday, October 13th. Shareholders of record on Friday, August 12th will be given a dividend of $0.494 per share. The ex-dividend date of this dividend is Wednesday, August 10th.

Other institutional investors have bought and sold shares of the company. Rhumbline Advisers raised its position in GlaxoSmithKline PLC by 5.1% in the fourth quarter. Rhumbline Advisers now owns 26,550 shares of the pharmaceutical company’s stock worth $1,071,000 after buying an additional 1,300 shares in the last quarter. Smith Salley & Associates raised its position in GlaxoSmithKline PLC by 45.7% in the fourth quarter. Smith Salley & Associates now owns 50,077 shares of the pharmaceutical company’s stock worth $2,020,000 after buying an additional 15,708 shares in the last quarter. Atlantic Trust Group LLC raised its position in GlaxoSmithKline PLC by 9.4% in the fourth quarter. Atlantic Trust Group LLC now owns 53,948 shares of the pharmaceutical company’s stock worth $2,177,000 after buying an additional 4,639 shares in the last quarter. Chesapeake Asset Management LLC raised its position in GlaxoSmithKline PLC by 95.9% in the fourth quarter. Chesapeake Asset Management LLC now owns 66,956 shares of the pharmaceutical company’s stock worth $2,702,000 after buying an additional 32,775 shares in the last quarter. Finally, MUFG Americas raised its position in GlaxoSmithKline PLC by 11.3% in the third quarter. MUFG Americas now owns 73,060 shares of the pharmaceutical company’s stock worth $2,809,000 after buying an additional 7,399 shares in the last quarter.

GlaxoSmithKline plc. (GSK) is a healthcare company that researches and develops pharmaceuticals, vaccines and consumer healthcare products. The Company operates in two segments: Pharmaceuticals and Vaccines, and Consumer Healthcare. The Pharmaceuticals segment develops and makes medicines to treat a range of acute and chronic diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.